Rezvilutamide for high-risk prostate cancer after surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called Rezvilutamide in men who have had surgery for high-risk prostate cancer and are not getting radiation therapy. The goal is to see if the drug can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have had surgery to remove your prostate for prostate cancer.
- Your doctor says you need medication treatment and you are in good physical condition (ECOG 0 or 1).
- Before surgery, scans showed no cancer spread to other parts of your body.
- You have at least one high-risk factor after surgery, like cancer at the edges of the removed tissue, or cancer in lymph nodes.
- You are not planning to get radiation therapy after surgery.
- Your current PSA level is below 0.1 ng/mL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
This trial tests if a daily pill called Rezvilutamide can prevent prostate cancer from returning in men who had their prostate removed and are at high risk of recurrence. It is for men who cannot or choose not to have radiation therapy.
This study looks at giving rezvilutamide, a hormone therapy pill, to men with high-risk prostate cancer before they have surgery. The goal is to see if it helps make the surgery more effective and improves outcomes.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
This trial tests if adding the drug rezvilutamide to standard hormone therapy, along with prostate removal surgery and precise radiation to cancer spots, helps men whose prostate cancer has spread to a limited number of places (no more than 10 spots, and not in organs like the liver or lungs).
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.